HEMATOLOGY Imatinib-should we have more of a good thing?

被引:0
|
作者
Apperley, Jane F. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London W12 0NN, England
关键词
CHRONIC MYELOID-LEUKEMIA; 800; MG; EXPRESSION; RISK;
D O I
10.1038/nrclinonc.2010.68
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?
引用
收藏
页码:303 / 304
页数:2
相关论文
共 50 条